Breakthrough in Bladder Cancer Treatment: Padcev and Keytruda Combination Shows Promising Results

Pharmaceutical companies Merck, Pfizer, and Astellas Pharma have reported promising results from their collaborative study on a combination therapy for muscle-invasive bladder cancer (MIBC). Presented at the European Society of Medical Oncology (ESMO) conference in Berlin, the study demonstrated that the combination of Padcev and Keytruda significantly reduces the risk of tumor recurrence, progression, or death by 60% compared to surgery alone. This research specifically targeted patients who were ineligible for or declined cisplatin-based chemotherapy, a common but harsh treatment option.

FiercePharmaReutersInvestor's Business DailyTriplet of Companies Sparks Major Hope for Bladder Cancer TreatmentESMO 2025 – Padcev plus Keytruda sets the perioperative bar

The study involved two patient groups: one underwent bladder and lymph node removal surgery, while the other received Padcev and Keytruda prior to surgery. The results indicated that patients who had surgery alone experienced their first event—relapse or death—at a median of 15.7 months. In contrast, the median event-free survival for those treated with the combination has not yet been established, suggesting a potential for extended survival without relapse fears. Astellas' Moitreyee Chatterjee-Kishore referred to these findings as “enormous new hope” for patients, while Merck's Marjorie Green described the results as “transformational.”

Triplet of Companies Sparks Major Hope for Bladder Cancer TreatmentInvestor's Business DailyFiercePharmaESMO 2025 – Padcev plus Keytruda sets the perioperative barReuters

The study also assessed overall survival rates, revealing that the median overall survival for the surgery group was 41.7 months. For the Padcev and Keytruda group, this statistic has not yet been reached, indicating a possibility for longer survival. Approximately 80% of patients treated with the combination have survived at least two years, compared to about 60% for those who underwent surgery alone. Furthermore, a pathologic complete response—indicating no signs of cancer in tissue samples—was observed in 57.1% of the Padcev/Keytruda group, compared to only 8.6% in the surgery group.

Triplet of Companies Sparks Major Hope for Bladder Cancer TreatmentInvestor's Business DailyFiercePharmaReutersESMO 2025 – Padcev plus Keytruda sets the perioperative bar

While the combination therapy shows promise, it is not without side effects. All patients reported some adverse reactions, primarily skin issues such as itching and rashes. The surgery group experienced a lower incidence of side effects at 64.8%. Chatterjee-Kishore emphasized the importance of exploring options that could delay surgery or reduce the need for it altogether, focusing on the nectin-4 protein prevalent in bladder cancer cells.

Triplet of Companies Sparks Major Hope for Bladder Cancer Treatment

Despite the positive results, there are concerns regarding the trial design and the implications for regulatory approval. Critics have noted that the FDA may scrutinize the contributions of neoadjuvant and adjuvant therapy in the treatment regimen. The companies are preparing to discuss these aspects with the FDA, emphasizing that both components are necessary for treatment efficacy.

FiercePharma

The findings from this study represent a potential shift in the treatment landscape for bladder cancer, particularly for patients who cannot tolerate traditional chemotherapy. As Merck, Pfizer, and Astellas continue their research, there is cautious optimism regarding the future of bladder cancer treatment, with hopes that these advancements will lead to improved patient outcomes and possibly a new standard of care.

Triplet of Companies Sparks Major Hope for Bladder Cancer Treatment